JAZZ PE Ratio & Valuation,Is JAZZ Overvalued

JAZZ Relative Valuation

JAZZ's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, JAZZ is overvalued; if below, it's undervalued.

Historical Valuation

Jazz Pharmaceuticals PLC (JAZZ) is now in the Undervalued zone, suggesting that its current forward PE ratio of 7.53 is considered Undervalued compared with the five-year average of 7.99. The fair price of Jazz Pharmaceuticals PLC (JAZZ) is between 326.07 to 411.13 according to relative valuation methord. Compared to the current price of 169.56 USD , Jazz Pharmaceuticals PLC is Undervalued By 48%.

Relative Value

Fair Zone

326.07-411.13

Current Price：169.56

48%

Undervalued

7.62

9.14

EV/EBITDA

Jazz Pharmaceuticals PLC. (JAZZ) has a current EV/EBITDA of 9.14. The 5-year average EV/EBITDA is 7.59. The thresholds are as follows: Strongly Undervalued below 4.85, Undervalued between 4.85 and 6.22, Fairly Valued between 8.96 and 6.22, Overvalued between 8.96 and 10.33, and Strongly Overvalued above 10.33. The current Forward EV/EBITDA of 9.14 falls within the Overvalued range.

7.09

EV/EBIT

Jazz Pharmaceuticals PLC. (JAZZ) has a current EV/EBIT of 7.09. The 5-year average EV/EBIT is 7.87. The thresholds are as follows: Strongly Undervalued below 4.65, Undervalued between 4.65 and 6.26, Fairly Valued between 9.48 and 6.26, Overvalued between 9.48 and 11.09, and Strongly Overvalued above 11.09. The current Forward EV/EBIT of 7.09 falls within the Historic Trend Line -Fairly Valued range.

2.33

Jazz Pharmaceuticals PLC. (JAZZ) has a current PS of 2.33. The 5-year average PS is 2.21. The thresholds are as follows: Strongly Undervalued below 1.26, Undervalued between 1.26 and 1.73, Fairly Valued between 2.68 and 1.73, Overvalued between 2.68 and 3.16, and Strongly Overvalued above 3.16. The current Forward PS of 2.33 falls within the Historic Trend Line -Fairly Valued range.

11.90

P/OCF

Jazz Pharmaceuticals PLC. (JAZZ) has a current P/OCF of 11.90. The 5-year average P/OCF is 6.90. The thresholds are as follows: Strongly Undervalued below 3.28, Undervalued between 3.28 and 5.09, Fairly Valued between 8.71 and 5.09, Overvalued between 8.71 and 10.52, and Strongly Overvalued above 10.52. The current Forward P/OCF of 11.90 falls within the Strongly Overvalued range.

7.40

P/FCF

Jazz Pharmaceuticals PLC. (JAZZ) has a current P/FCF of 7.40. The 5-year average P/FCF is 6.62. The thresholds are as follows: Strongly Undervalued below 3.70, Undervalued between 3.70 and 5.16, Fairly Valued between 8.08 and 5.16, Overvalued between 8.08 and 9.54, and Strongly Overvalued above 9.54. The current Forward P/FCF of 7.40 falls within the Historic Trend Line -Fairly Valued range.

Jazz Pharmaceuticals PLC (JAZZ) has a current Price-to-Book (P/B) ratio of 2.57. Compared to its 3-year average P/B ratio of 2.15 , the current P/B ratio is approximately 19.77% higher. Relative to its 5-year average P/B ratio of 2.31, the current P/B ratio is about 11.06% higher. Jazz Pharmaceuticals PLC (JAZZ) has a Forward Free Cash Flow (FCF) yield of approximately 13.13%. Compared to its 3-year average FCF yield of 15.82%, the current FCF yield is approximately -16.97% lower. Relative to its 5-year average FCF yield of 13.11% , the current FCF yield is about 0.20% lower.

2.60

P/B

Median3y

2.15

Median5y

2.31

13.13

FCF Yield

Median3y

15.82

Median5y

13.11

Competitors Valuation Multiple

The average P/S ratio for JAZZ's competitors is 0.00, providing a benchmark for relative valuation. Jazz Pharmaceuticals PLC Corp (JAZZ) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 6.74%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of JAZZ increased by 37.66% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -23.07 to -28.00.

The secondary factor is the Margin Expansion, contributed 9.57%to the performance.

Overall, the performance of JAZZ in the past 1 year is driven by P/E Change. Which is more unsustainable.

6.74%

1.05B → 1.13B

Revenue Growth

9.57%

20.38 → 22.33

Margin Expansion

21.35%

-23.07 → -28.00

P/E Change

37.66%

123.15 → 169.53

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Jazz Pharmaceuticals PLC (JAZZ) currently overvalued or undervalued?

What is Jazz Pharmaceuticals PLC (JAZZ) fair value?

JAZZ's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Jazz Pharmaceuticals PLC (JAZZ) is between 326.07 to 411.13 according to relative valuation methord.

How does JAZZ's valuation metrics compare to the industry average?

What is the current P/B ratio for Jazz Pharmaceuticals PLC (JAZZ) as of Dec 16 2025?

As of Dec 16 2025, Jazz Pharmaceuticals PLC (JAZZ) has a P/B ratio of 2.57. This indicates that the market values JAZZ at 2.57 times its book value.

What is the current FCF Yield for Jazz Pharmaceuticals PLC (JAZZ) as of Dec 16 2025?

As of Dec 16 2025, Jazz Pharmaceuticals PLC (JAZZ) has a FCF Yield of 13.13%. This means that for every dollar of Jazz Pharmaceuticals PLC’s market capitalization, the company generates 13.13 cents in free cash flow.

What is the current Forward P/E ratio for Jazz Pharmaceuticals PLC (JAZZ) as of Dec 16 2025?

As of Dec 16 2025, Jazz Pharmaceuticals PLC (JAZZ) has a Forward P/E ratio of 7.53. This means the market is willing to pay $7.53 for every dollar of Jazz Pharmaceuticals PLC’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Jazz Pharmaceuticals PLC (JAZZ) as of Dec 16 2025?

As of Dec 16 2025, Jazz Pharmaceuticals PLC (JAZZ) has a Forward P/S ratio of 2.33. This means the market is valuing JAZZ at $2.33 for every dollar of expected revenue over the next 12 months.

JAZZ Valuation